Realizing the Potential of Anti-SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management

JAMA. 2022 Feb 1;327(5):427-429. doi: 10.1001/jama.2021.19994.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19*
  • Humans
  • SARS-CoV-2

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antibodies, Viral